Evidence map›Paper›PMID 28626169›Full record

ArticleInternal medicine (Tokyo, Japan)2017

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease.

Yusuke Kawamura, Kenji Ikeda, Yasuji Arase, Shunichiro Fujiyama, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki and 2 more

Abstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yusuke KawamuraDepartment of Hepatology, Toranomon Hospital, Japan.
Kenji IkedaDepartment of Hepatology, Toranomon Hospital, Japan.
Yasuji AraseDepartment of Hepatology, Toranomon Hospital, Japan.
Shunichiro FujiyamaDepartment of Hepatology, Toranomon Hospital, Japan.
Tetsuya HosakaDepartment of Hepatology, Toranomon Hospital, Japan.
Masahiro KobayashiDepartment of Hepatology, Toranomon Hospital, Japan.
Satoshi SaitohDepartment of Hepatology, Toranomon Hospital, Japan.
Hitomi SezakiDepartment of Hepatology, Toranomon Hospital, Japan.
Norio AkutaDepartment of Hepatology, Toranomon Hospital, Japan.
Fumitaka SuzukiDepartment of Hepatology, Toranomon Hospital, Japan.
Yoshiyuki SuzukiDepartment of Hepatology, Toranomon Hospital, Japan.
Hiromitsu KumadaDepartment of Hepatology, Toranomon Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To detect the aggressive phenotype (AP) of non-alcoholic fatty liver disease (NAFLD) based on the initial laboratory data and clinical characteristics. Methods We enrolled 144 patients with histologically proven NAFLD. For the first analysis, 24 NAFLD patients underwent repeat biopsy to establish a discriminant formula for predicting the AP of NAFLD (D-APN). The AP was defined by NAFLD that had been maintained or progressed to a fibrotic stage beyond stage 2. In the second analysis, we analyzed the distribution of the AP in each stage of disease and the incidence of the PNPLA3 rs738409 GG genotype in AP in 120 other patients. Results After the analysis, the following function was found to discriminate the disease phenotype: z=0.150×body mass index (kg/m

Indexed as

AcyltransferasesAdultAgedAge FactorsBiopsyBody Mass IndexDisease ProgressionFemaleFibrosisGenotypeHumansLipaseMaleMembrane ProteinsMiddle AgedNon-alcoholic Fatty Liver DiseaseAcyltransferasesLipaseMembrane ProteinsPhospholipases A2, Calcium-IndependentPNPLA3 protein, humanaggressivefibrosishepatocellular carcinomanon-alcoholic fatty liver diseasephenotype

Identifiers

PMID28626169
PMCPMC5505899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.